ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares of Stock

Posted by George Bondi on Oct 8th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) CEO Michael Farrell sold 4,991 shares of the firm’s stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $226.33, for a total transaction of $1,129,613.03. Following the completion of the sale, the chief executive officer directly owned 479,803 shares in the company, valued at approximately $108,593,812.99. This trade represents a 1.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Stock Up 0.2%

ResMed stock traded up $0.54 during trading on Thursday, reaching $226.52. The stock had a trading volume of 651,064 shares, compared to its average volume of 1,299,688. The company has a quick ratio of 2.42, a current ratio of 3.10 and a debt-to-equity ratio of 0.06. ResMed Inc. has a 52-week low of $180.26 and a 52-week high of $284.05. The stock has a market cap of $31.86 billion, a PE ratio of 21.72, a P/E/G ratio of 1.39 and a beta of 0.75. The business has a 50 day moving average price of $224.88 and a 200 day moving average price of $213.87.

ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.89 by $0.06. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.46 billion. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period last year, the business earned $2.55 EPS. On average, analysts predict that ResMed Inc. will post 12.07 EPS for the current year.

ResMed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 24th. Investors of record on Thursday, August 20th were issued a $0.66 dividend. This represents a $2.64 annualized dividend and a yield of 1.2%. This is a boost from ResMed’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Thursday, August 20th. ResMed’s dividend payout ratio is currently 25.31%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Robert W. Baird set a $213.00 price objective on ResMed in a research report on Friday, August 7th. Weiss Ratings raised ResMed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Citigroup restated a “neutral” rating on shares of ResMed in a research note on Thursday, September 10th. UBS Group reiterated a “buy” rating and issued a $300.00 price target on shares of ResMed in a research note on Tuesday, July 21st. Finally, Jefferies Financial Group cut their price objective on shares of ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday, July 10th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $241.69.

Read Our Latest Research Report on RMD

Institutional Trading of ResMed

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bell Investment Advisors Inc purchased a new stake in ResMed in the second quarter valued at approximately $26,000. Reflection Asset Management purchased a new position in shares of ResMed during the fourth quarter worth approximately $34,000. Trust Co. of Vermont acquired a new position in shares of ResMed in the 2nd quarter valued at $39,000. MV Capital Management Inc. acquired a new position in shares of ResMed in the 4th quarter valued at $52,000. Finally, Kelleher Financial Advisors purchased a new stake in ResMed in the 2nd quarter valued at $47,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

About ResMed

(Get Free Report)

ResMed Inc (NYSE: RMD) develops, manufactures and distributes medical equipment and digital health solutions for sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its products include continuous positive airway pressure (CPAP), bilevel and other noninvasive ventilation devices, as well as masks, humidifiers, accessories and diagnostic equipment.

The company also provides cloud-connected software and digital health services that support patient monitoring, therapy management and communication among patients, clinicians and care providers.